

## Disclosure of received notification

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification on 6 August 2015 from Danske Bank concerning the acquisition of voting securities. The shareholding of Danske Bank crossed the disclosure threshold of 3% through the acquisition of voting securities.

Based on the denominator of 32,111,827 (total number of voting rights) and the latest received notifications, the major shareholders of Fagron are:

	Number of shares	% of effective voting rights
Carmignac Gestion	2,463,267	7.67%
TIAA-CREF Asset Management LLC	1,635,681	5.09%
BNP Paribas Investment Partners SA	1,609,182	5.01%
Fidelity Management and Research (FMR LLC)	1,517,822	4.73%
Danske Bank	1,029,558	3.21%

The original notification forms are available on the website [investors.fagron.com](http://investors.fagron.com).

### Fagron profile

Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

### For further information

Jan Peeters  
Chief Financial Officer  
Tel. +31 88 331 12 52  
[jan.peeters@fagron.com](mailto:jan.peeters@fagron.com)

Marieke Palstra  
Global Investor Relations Director  
Tel. +31 88 331 12 13  
[marieke.palstra@fagron.com](mailto:marieke.palstra@fagron.com)

<sup>1</sup> This press release was sent out by Fagron NV and Fagron BV.

